logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Cancer Enterprise Global Pipeline

As of May 2017

These are investigational agents and are not approved by the EMA, FDA or any other worldwide regulatory agency as a treatment for any indication. Efficacy and safety have not been established. There is no guarantee that these investigational agents will become commercially available.

ADC Franchise

Compound Tumor Type Relevant Pathway Highest Phase of Development Location
DS-8201 Breast Cancer, Gastric Cancer HER2 Phase 1 US / Japan
U3-1402 Breast Cancer HER2 Phase 1 Japan
DS-7300 Solid Tumours B7-H3 Preclinical --
DS-1062 Solid Tumours TROP2 Preclinical --
Project 5 Solid Tumours Undisclosed Preclinical --
Project 6 Solid Tumours Undisclosed Preclinical --

AML Franchise

Compound Tumor Type Relevant Pathway Highest Phase of Development Location
Quizartinib (AC220) Newly-Diagnosed Acute Myeloid Leukemia FLT3 Phase 3 US / EU/ Asia
Quizartinib (AC220) Relapsed/Refractory AML FLT3 Phase 3 US / EU/ Asia
Quizartinib (AC220) Relapsed/Refractory AML FLT3 Phase 1 Japan
DS-3032 AML, Acute Lymphotic Leukemia (ALL), Chronic Myeloid Leukemia (CML), Myelodysplastic Syndrome (MDS) MDM2 Phase 1 US
DS-3032 Solid Tumours, Lymphoma MDM2 Phase 1 Japan
DS-3201 AML, ALL EZH1/2 Phase 1 US
DS-3201 Non-Hodgkin's Lymphoma EZH1/2 Phase 1 Japan
PLX51107 AML, MDS, Lymphoma, Solid Tumours BRD4 Phase 1 US
DS-1001 AML IDH1 Preclinical --

Additional Late and Early Stage Programs

Compound Tumor Type Relevant Pathway Highest Phase of Development Location
Pexidartinib (PLX3397) Tenosynovial Giant Cell Tumor (TGCT)*, FDA Breakthrough Designation CSF-1R Phase 3 US/EU
Pexidartinib (PLX3397) Glioblastoma CSF-1R, c-KIT Phase 2 US
Pexidartinib (PLX3397) Melanoma c-KIT Phase 1/2 Asia
Pexidartinib (PLX3397) Solid Tumors CSF-1R Phase 1 Asia
Pexidartinib (PLX3397) Solid Tumors, Melanoma CSF-1R Phase 1/2 US
Pexidartinib (PLX3397) [in combination with pembrolizumab] Solid Tumors, Melanoma CSF-1R Phase 1/2 US
Patritumab (U3-1287) Head and Neck Cancer HER3 Phase 2 EU
DS-1647 Glioblastoma SAKIGAKE Designation Oncolytic HSV-1 Phase 2 Japan
PLX7486 Solid Tumors FMS/TRK Phase 1 US
PLX8394 Solid Tumor BRAF Phase 1 US
DS-8273 Solid Tumors DR5 Phase 1 US
DS-6051 Solid Tumors NTRK/ROS1 Phase 1 US/Japan
PLX9486 Solid Tumors KIT Phase 1 US
PLX73086 TGCT CSF-1R Phase 1 US
DS-1123 Solid Tumors FGFR2 Phase 1 Japan
DS-1001 Gliomas IDH1 Phase 1 Japan

*Tenosynovial giant cell tumor (TGCT) is also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS).